Log In
Print this Print this

Cotara (TNT-1 mAB) (131I-chTNT-1/B)

  Manage Alerts
Collapse Summary General Information
Company Peregrine Pharmaceuticals Inc.
DescriptionRadioactive chimeric tumor necrosis therapy (TNT) mAb that binds a DNA/histone complex
Molecular Target DNA/histone complex
Mechanism of ActionRadiolabelled antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationBrain cancer
Indication DetailsTreat advanced glioblastoma (brain cancer); Treat anaplastic astrocytoma; Treat glioblastoma multiforme (GBM); Treat glioma; Treat malignant glioma; Treat recurrent glioblastoma multiforme (GBM)
Regulatory Designation

U.S. - Fast Track (Treat anaplastic astrocytoma);
U.S. - Fast Track (Treat glioblastoma multiforme (GBM));
U.S. - Orphan Drug (Treat glioblastoma multiforme (GBM));
U.S. - Orphan Drug (Treat anaplastic astrocytoma);
EU - Orphan Drug (Treat glioma)


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today